Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Department of Molecular Virology, Pasteur Institute of Iran, Tehran, Iran.
Arch Virol. 2021 Apr;166(4):995-1006. doi: 10.1007/s00705-021-04964-9. Epub 2021 Feb 3.
Due to the lower efficacy of currently approved live attenuated rotavirus (RV) vaccines in developing countries, a new approach to the development of safe mucosally administered live bacterial vectors is being considered, using probiotic bacteria as an efficient delivery platform for heterologous RV antigens. Lactic acid bacteria (LAB), which are considered food-grade bacteria and normal microbiota, have been utilized throughout history as probiotics and developed since the 1990s as a delivery system for recombinant heterologous proteins. Over the last decade, LAB have frequently been used as a platform for the delivery of various RV antigens to the mucosa. Given the appropriate safety profile for neonates and providing the benefits of probiotics, recombinant LAB-based vaccines could potentially address the need for a subunit RV vaccine. The present review focuses mainly on different recombinant LAB vaccine constructs for RV and their potential as an alternative recombinant vaccine against RV disease.
由于目前批准的减毒活轮状病毒 (RV) 疫苗在发展中国家的效果较低，因此正在考虑采用新方法来开发安全的黏膜给予的活细菌载体，使用益生菌作为异源 RV 抗原的有效传递平台。乳酸菌 (LAB) 被认为是食品级细菌和正常微生物群，历史上一直被用作益生菌，并自 20 世纪 90 年代以来被开发为重组异源蛋白的传递系统。在过去的十年中，LAB 经常被用作向黏膜传递各种 RV 抗原的平台。鉴于对新生儿的适当安全性概况并提供益生菌的益处，基于重组 LAB 的疫苗有可能满足对 RV 亚单位疫苗的需求。本综述主要集中在用于 RV 的不同重组 LAB 疫苗构建体及其作为 RV 疾病替代重组疫苗的潜力。
